Appling and Johnston will be based in the company’s Queensbury, New York facility and report to the executive vice president of Research and Development, and Delcath’s chief medical officer, Krishna Kandarpa.

Most recently, Appling served as the senior vice president of Research and Development in AngioDynamics and was responsible for advanced research, process engineering and managing an intellectual property portfolio of 285 issued patents and patent applications.

Johnston worked as the principal research scientist in the Translational Medicine group at Pfizer.

Delcath Systems is a development stage, specialty medical device and pharmaceutical company focused on oncology.

Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.